Comparative Pharmacology
Head-to-head clinical analysis: RECORLEV versus THYROLAR 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RECORLEV versus THYROLAR 1.
RECORLEV vs THYROLAR-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RECORLEV (levoketoconazole) is an orally administered corticosteroid biosynthesis inhibitor that suppresses cortisol production by inhibiting adrenal and gonadal steroidogenic enzymes, particularly CYP17A1 (17α-hydroxylase and 17,20-lyase) and CYP11B1 (11β-hydroxylase). It also weakly inhibits CYP3A4 and other CYP enzymes.
Thyrolar-1 is a combination of levothyroxine (T4) and liothyronine (T3). T4 is converted to the active hormone T3 in peripheral tissues. Both forms bind to thyroid hormone receptors, which regulate gene transcription, influencing metabolism, growth, and development.
150 mg orally twice daily with a high-fat meal.
Oral: 30-60 mg liothyronine (T3) daily, typically initiated at 15 mg/day and titrated upward based on clinical response. Usual maintenance dose 25-50 mg/day.
None Documented
None Documented
18 hours; prolonged in renal impairment (up to 45 hours in CrCl <30 mL/min)
Levothyroxine (T4): 6–7 days; Liothyronine (T3): 1–2 days. In hyperthyroidism, T4 half-life may be reduced to 3–4 days; in hypothyroidism, prolonged to 9–10 days.
Renal: 85% as unchanged drug; Fecal: 10% as metabolites
Renal excretion of iodide; after deiodination of T3 and T4, iodine is excreted in urine (∼80%) and feces (∼20%).
Category C
Category C
Thyroid Hormone
Thyroid Hormone